The main purpose of this study is to investigate the safety of LY3981314 when administered subcutaneously (SC) (under the skin), and how it's processed in the body.
The study will last approximately 25 weeks, excluding a screening period with an optional extension to approximately 49 weeks for qualifying participants.
Protocol Amendment History
3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-03; most recent amendment 2026-05-18.
Status change: Recruiting → Active, Not Recruiting2026-05-18
Status change: Not Yet Recruiting → Recruiting2025-07-01